Key Drivers
- Revenue scale
- Negative profitability
- Cash burn
AIAI Summary
Clover's investment thesis has shifted from a pure growth roll‑up to an execution‑dependent margin‑recovery story: the company can reach GAAP profitability by 2026 if it accelerates conversion of new members into the profitable cohort base and reverses pharmacy/BER trends, but failure to do so will keep EBITDA gains fragile and cash burning. Monitor quarter‑over‑quarter cohort contribution margins, BER trajectory, and operating cash flow as the decisive, actionable KPIs for validating the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Revenue scale
- •Negative profitability
- •Cash burn
Clover Health shows solid revenue and no debt but is loss-making with negative margins, worsening quarterly EBITDA, and ongoing cash burn that undermines its near-term investability.
Price Behavior
Key Price Behavior Insights:
- •Modest downtrend
- •Below SMA
- •Support holding
Over the last month the stock slipped from $2.02 to $1.89 and is trading below the last-month SMA (~$2.01) with RSI ~40, leaving immediate support at $1.88–$1.89 (a break confirms further downside) and resistance near $2.01 and $2.16 to shift bias bullish.
Modest decline from $2.02 to $1.89 over the last month
Sentiment & News
Key News Insights:
- •Membership surge
- •Interoperability milestone
- •Margin headwinds
Clover Health posted rapid Medicare Advantage membership and revenue growth with 2025 adjusted-EBITDA profitability and 2026 guidance for stronger membership and GAAP profit, while delivering interoperability and clinical-product milestones amid margin and policy headwinds.
The mix of accelerating topline, improving unit economics, and tangible product wins supports upside to valuation if medical-cost trends and policy risks are contained
Similar Companies in Healthcare
Other companies in the same sector with AI ratings